Rather than relying on conventional cell lines that have defined effective drug targets for other types of cancers, they are creating and sequencing cell lines from a cancer patient’s own tissue. Their results, outlined August 4 in Cell Reports, reveal that pancreatic tumors are more varied than previously thought and that drug sensitivity is unique to each patient. Read more . . .
A team led by University of Arizona researchers is taking a new, patient-directed approach to treating pancreatic cancer.